Physician profile
Sohrab Khaladj
NPI 1306154828
$8,450.94
in general payments reported to CMS, 2019-2025
16 companies · $482 in 2025
The $482 reported for 2025 was more than what 89% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,793 · 2020: $895 · 2021: $1,597 · 2022: $1,291 · 2023: $1,621 · 2024: $772 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,524 · Consulting Fee: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,523.53 |
| Consulting Fee | $351.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,294.75 | 2019-2024 | Xarelto |
| Horizon Therapeutics Plc | $1,451.39 | 2019-2023 | Krystexxa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $956.26 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $926.27 | 2019-2023 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $475.42 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $449.81 | 2019-2025 | |
| Adma Biomanufacturing LLC | $428.34 | 2022-2025 | |
| Glaxosmithkline, LLC. | $343.98 | 2023 | Arexvy |
| Amgen INC. | $256.48 | 2024 | Krystexxa |
| Pfizer INC. | $250.21 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.54 | 2025 | Jardiance |
| Abbvie INC. | $127.80 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Portola Pharmaceuticals, LLC | $119.57 | 2019 | |
| Heartflow, INC. | $58.96 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $22.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohrab Khaladj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.